Catalyst Reaction · NASDAQ: ZURA · Biotechnology
Zura Bio (ZURA): Phase 2 data, a 69.7% drop and what followed
Zura Bio (ZURA) released clinical update on Phase 2 TibuSHIELD study of tibulizumab (ZB-106) at 7:00 AM ET on Monday, November 9, and the stock went from Friday’s $4.09 close to as low as $0.9342. It finished the session −69.7% at $1.24 on 12.5 times its 20-day average volume. Here is how it traded, turn by turn, and how LiveChart’s stack read each one.
By IndicatorStack · · All times ET
The catalyst
What the company released or filed, to the minute it crossed. It’s in the timeline as a shaded row, linked to the source.
How it traded
The price around it, session by session: the gap, the range, the close, with the chart LiveChart draws from those bars.
How the stack read it
LiveChart’s read at each turn: the 5-minute trend (the stack bias), the higher timeframes (Compass), the flow (Undertow) and traps (Tripwire).
How the stack read it, checkpoint by checkpoint
The stack bias is LiveChart’s read of the 5-minute trend at that moment: a green dot is bullish, red bearish, grey no clear direction. Under it, what Compass read on the higher timeframes the trend is measured against.
- BeforeBullishFri close · $4.08Higher timeframes up
- Into the openBearishMon 9:30 AM · $1.27Tailwind down
- 30 minutes inBearishMon 10:00 AM · $1.07Tailwind down
- At the closeBullishMon 4:00 PM · $1.24Higher timeframes still down
- Tuesday’s closeNeutralTue 4:00 PM · $1.41Tailwind down
- Wednesday’s closeBearishWed 4:00 PM · $1.42Tailwind down
- Thursday’s closeBearishThu 4:00 PM · $1.24Tailwind down
The timeline
Everything that happened, in order, on one ET clock: the company’s releases and SEC filings next to the price and the stack’s own turns.
- ReleaseSECShaded rows are the catalyst: the company’s own releases and filings
- PriceThe session’s open, high, low and close
- StackLiveChart’s 5-minute bias changed
- TriggerA hypothetical entry at the default settings
- TripwireA break of a level that failed to hold
Monday, November 9
- PricePremarket high $4.27+4.4% from the prior close
- ReleaseClinical update on Phase 2 TibuSHIELD study of tibulizumab (ZB-106)Press release, Business Wire
- SECCurrent report (Form 8-K) filedAccepted by the SEC at 7:07:11 AM ET
- Stack5-minute stack bias turned bearishat $1.27
- PriceOpened at $1.27−68.9% from Friday’s $4.09 close
- TripwireTripwire flagged a trap at the lowsa push through support that failed to hold, at $0.9649
- PriceSession low $0.9342
- Stack5-minute stack bias went neutralat $1.13, its inputs no longer agreeing
- TripwireTripwire flagged a trap at the highsa push through resistance that failed to hold, at $1.14
- Stack5-minute stack bias turned bullishat $1.14
- PriceClosed at $1.24, −69.7% on the day64.3M shares, 12.5× its 20-day average
Tuesday, November 10
- Stack5-minute stack bias turned bearishat $1.20
- ReleaseInvestors Have Opportunity to Join Zura Bio Limited Fraud InvestigationPress release, Business Wire
- PriceSession low $1.16
- PriceOpened at $1.17−5.6% from Monday’s $1.24 close
- Stack5-minute stack bias went neutralat $1.33, its inputs no longer agreeing
- Stack5-minute stack bias turned bullishat $1.42
- ReleaseSHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors ofPress release, PRNewsWire
- PriceSession high $1.53
- Stack5-minute stack bias went neutralat $1.37, its inputs no longer agreeing
- Stack5-minute stack bias turned bearishat $1.37
- Stack5-minute stack bias went neutralat $1.41, its inputs no longer agreeing
- PriceClosed at $1.41, +13.7% on the day17M shares, 2.1× its 20-day average
Wednesday, November 11
- PriceOpened at $1.41+0.0% from Tuesday’s $1.41 close
- Stack5-minute stack bias went neutralat $1.39, its inputs no longer agreeing
- Stack5-minute stack bias turned bearishat $1.39
- PriceSession low $1.35
- Stack5-minute stack bias went neutralat $1.42, its inputs no longer agreeing
- Stack5-minute stack bias turned bullishat $1.45
- PriceSession high $1.58
- Stack5-minute stack bias went neutralat $1.49, its inputs no longer agreeing
- Stack5-minute stack bias turned bearishat $1.45
- PriceClosed at $1.43, +1.4% on the day6.9M shares, 0.9× its 20-day average
Thursday, November 12
- Stack5-minute stack bias turned bearishat $1.41
- PriceOpened at $1.41−1.4% from Wednesday’s $1.43 close
- PriceSession low $1.21
- PriceClosed at $1.24, −13.3% on the day3.5M shares, 0.4× its 20-day average
Friday, November 6
Before the catalyst
Zura Bio closed Friday at $4.09. The 5-minute stack bias was bullish (firm), since 11:20 AM: held from earlier bars; none of its inputs pull its way on this bar. Compass read “Higher timeframes up” (15m ↗ 1h ↗ 2h ↗ 4h ↗ D ↘). Undertow: volume surge, sellers hitting the bid. Tripwire: Longs: Avoid, support looks fake, heavy tape on it. Its Next row read “Lost VWAP 4.08, buyers need a reclaim”.
Over the year before, it had traded between $3.25 and $7.44. The daily chart below shows where it was trading, and the bar the catalyst printed.
Bullishfirm · 5m stack bias · $4.08
- Compass
- Higher timeframes up
- Undertow
- Volume surge
- Tripwire
- Longs: Avoid
- Next
- Lost VWAP 4.08, buyers need a reclaim
Monday, November 9
The Phase 2 data and a 69.7% drop
The release crossed at 7:00 AM ET, with the company’s Form 8-K accepted by the SEC at 7:07 AM. Premarket trading carried it to $4.27 by 4:00 AM, +4% from the prior close, on 559K shares before the bell. It opened at $1.27, −68.9%, and the regular session ranged from $0.9342 to $1.27 before closing at $1.24. It did this on a day SPY rose 2.4% and XBI, the biotechnology ETF, rose 3.1%.
Into the open the stack read it as bearish (weakening) with 5 of 5 higher timeframes down, and Undertow read “volume surge”. Thirty minutes in, the picture had changed: price was below VWAP at $1.16 and the Next row read “Stretched below the averages, bounce area near 1.13”. By the close the 5-minute bias was bullish from 12:40 PM, while Compass still read “Higher timeframes still down”: the day’s trend on the 5-minute chart had turned while the higher timeframes it is measured against had not.
Bearishweakening · 5m stack bias · $1.27
- Compass
- Tailwind down
- Undertow
- Volume surge
- Tripwire
- Shorts: Avoid
- Next
- Trend down, fast EMA at 1.28, longs run against the bias
Bearishstrong · 5m stack bias · $1.07
- Compass
- Tailwind down
- Undertow
- Sellers in control
- Tripwire
- Shorts: Clean
- Next
- Stretched below the averages, bounce area near 1.13
Bullishstrong · 5m stack bias · $1.24
- Compass
- Higher timeframes still down
- Undertow
- Volume surge
- Tripwire
- Longs: Clean
- Next
- Buying drying up near 1.22, giveback risk rising
Tuesday, November 10
The session after
It opened at $1.17 (−5.6%) and traded from $1.16 to $1.53, closing at $1.41, +13.7% on 17M shares, still 2.1 times its 20-day average. The 5-minute stack bias was neutral, its inputs disagreeing. Compass read “Tailwind down” (15m ↑ 1h ↘ 2h ↘ 4h ↓ D ↘). Undertow: volume surge, buyers hitting the offer. Tripwire: Longs: Clean, nothing major in the way.
Neutral5m stack bias · $1.41
- Compass
- Tailwind down
- Undertow
- Volume surge
- Tripwire
- Longs: Clean
- Next
- Range 1.35 to 1.44, no edge in the middle
Wednesday, November 11
The session after
It opened at $1.41 (+0.0%) and traded from $1.35 to $1.58, closing at $1.43, +1.4% on 6.9M shares, still 0.9 times its 20-day average. The 5-minute stack bias was bearish (strong), since 2:55 PM: under VWAP 1.46 and a falling SMA, momentum down, net selling and trend strength with the sellers. Compass read “Tailwind down” (15m ↓ 1h ↓ 2h ↓ 4h ↓ D ↘). Undertow: volume surge, sellers hitting the bid. Tripwire: Shorts: Clean, nothing major in the way.
Bearishstrong · 5m stack bias · $1.42
- Compass
- Tailwind down
- Undertow
- Volume surge
- Tripwire
- Shorts: Clean
- Next
- Selling drying up at 1.42, squeeze risk rising
Thursday, November 12
The session after
It opened at $1.41 (−1.4%) and traded from $1.21 to $1.44, closing at $1.24, −13.3% on 3.5M shares, still 0.4 times its 20-day average. The 5-minute stack bias was bearish (weakening), since 7:25 AM: under VWAP 1.26 and trend strength with the sellers. Compass read “Tailwind down” (15m ↓ 1h ↘ 2h ↘ 4h ↓ D ↓). Undertow: volume surge, buyers hitting the offer. Tripwire: Shorts: Avoid, resistance looks thin, buying tape on it.
After hours it last traded at $1.23, with Undertow reading “buyers pushing back”.
Bearishweakening · 5m stack bias · $1.24
- Compass
- Tailwind down
- Undertow
- Volume surge
- Tripwire
- Shorts: Avoid
- Next
- Bounce, resistance to hold at 1.26 (VWAP)
Bearishweakening · 5m stack bias · $1.23
- Compass
- Tailwind down
- Undertow
- Buyers pushing back
- Tripwire
- Shorts: Avoid
- Next
- Trend down, fast EMA at 1.23, longs run against the bias
Shares, float and insiders
The supply picture
What the company has outstanding, and what its insiders and its share history show, from its SEC filings.
- Shares outstanding
- 96.3Mas reported to the SEC
- Float
- 45.6M47% of shares outstanding
- Last insider purchase
- February 26, 20262M shares at $6.25 by AI Biotechnology LLC (10 percent owner)
- Last insider sale
- November 25, 20241M shares at $2.73
Releases and filings
Sources
The company’s own releases and its filings with the SEC, newest first, each with the time it crossed.
- ReleaseSHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors ofTue Nov 10, 10:09 AM ET · PRNewsWire
- ReleaseInvestors Have Opportunity to Join Zura Bio Limited Fraud InvestigationTue Nov 10, 8:33 AM ET · Business Wire
- SECCurrent report (Form 8-K)Mon Nov 9, 7:07 AM ET · SEC EDGAR
- ReleaseClinical update on Phase 2 TibuSHIELD study of tibulizumab (ZB-106)Mon Nov 9, 7:00 AM ET · Business Wire
In short
Questions
Why did ZURA stock go down on November 9?
Zura Bio (ZURA) released clinical update on Phase 2 TibuSHIELD study of tibulizumab (ZB-106) at 7:00 AM ET on Monday, November 9, and the stock went from Friday’s $4.09 close to as low as $0.9342. It finished the session −69.7% at $1.24 on 12.5 times its 20-day average volume. The reaction describes the sequence and infers no cause.
What did Zura Bio announce on November 9, 2026?
Zura Bio (ZURA) released clinical update on Phase 2 TibuSHIELD study of tibulizumab (ZB-106) at 7:00 AM ET on Monday, November 9. The company’s release and its Form 8-K are linked in the sources on this page.
How did ZURA stock trade on November 9?
ZURA opened at $1.27, −68.9% from the prior close of $4.09, traded between $0.9342 and $1.27 in the regular session and closed at $1.24, −69.7%, on 64.3M shares.
How did LiveChart’s stack read ZURA at the close on November 9?
At the 4:00 PM ET close the 5-minute stack bias on ZURA was bullish (strong), Compass read “Higher timeframes still down” and Undertow read “volume surge”. Each turn of the read is on this page’s timeline.
What does LiveChart’s stack read on ZURA now?
The read on this page is fixed at each moment it describes. LiveChart reads ZURA on every bar as it trades: open it on LiveChart for the current stack bias, levels and every layer.
Every catalyst on ZURA
ZURA’s catalyst history
This is ZURA’s first Catalyst Reaction. Each time it moves on a release or a filing again, the reads line up here side by side, so how it reacts to its own news builds into a history.
| Session | The catalyst | The day | Next session | Stack bias at the close |
|---|---|---|---|---|
| Nov 9, 2026This reaction | Clinical update on Phase 2 TibuSHIELD study of tibulizumab (ZB-106)Trial data · 7:00 AM ET | −69.7% | +13.7% | Bullish |
Also on Monday, November 9
More Catalyst Reactions from that session
- Nov 99:01 AM ETTLS+48.8%Telos (TLS): quarterly results, a 48.8% session and what followedEarnings5.1× avg volume
- Nov 97:30 AM ETNCPL+44.4%Netcapital (NCPL): receives Nasdaq Extension to regain compliance, a 44.4% session and what followedCompany news0.8× avg volume
- Nov 97:00 AM ETFTH−42.5%Faeth Therapeutics (FTH): Phase 2 data, a 42.5% drop and what followedTrial data10.6× avg volume
- Nov 96:32 AM ETSOC−54.4%Sable Offshore (SOC): quarterly results, a 54.4% drop and what followedEarnings32.8× avg volume
- Nov 96:01 AM ETCKX+58.1%CKX (CKX): Brad Jacobs to lead $1 billion equity investment, a 58.1% session and what followedCompany news7,163.7× avg volume
- Nov 95:30 PM ETXHLD+49.5%TEN (XHLD): quarterly results, a 49.5% session and what followedEarnings12.4× avg volume
Every Reaction From Nov 9More Trial Data ReactionsZURA Catalyst HistoryZURA on LiveChartTechnical Setups RadarAll Catalyst ReactionsIntraday Movers
Further reading: Gaps: continuation and exhaustionLow-float riskWhat VWAP tells youTrading around halts
General market information from the company’s releases, its SEC filings, the session’s prices and LiveChart’s reads. Prices are indicative. It describes what happened and when, infers no cause, takes no view on what comes next and is not a recommendation to buy or sell any security. Trigger trades are hypothetical. Read the Risk Disclosure.